Dynamics of clonal evolution in myelodysplastic syndromes

Area of Science:

• Hematology
• Genetics
• Oncology

Background:

• Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders.
• Understanding mutation roles is crucial for MDS prognosis and treatment.
• Clonal dynamics significantly influence disease progression and outcomes.

Purpose of the Study:

• To differentiate the roles of various mutations in myelodysplastic syndromes (MDS).
• To investigate clonal dynamics and mutational enrichment patterns during MDS progression.
• To assess the impact of distinct mutation types on secondary acute myeloid leukemia (sAML) development and survival.

Main Methods:

• Whole-exome and targeted sequencing of 699 MDS patients, with 122 analyzed longitudinally.
• Analysis of mutational enrichment patterns in a total of 2,250 patients, incorporating previous reports.
• Comparative analysis of mutation types in high-risk MDS versus sAML.

Main Results:

• MDS progression is characterized by increased mutation number, diversity, and clone size.
• Type 1 mutations (FLT3, PTPN11, WT1, IDH1, NPM1, IDH2, NRAS) are enriched in sAML, newly acquired, and linked to faster progression and shorter survival.
• Type 2 mutations (TP53, GATA2, KRAS, RUNX1, STAG2, ASXL1, ZRSR2, TET2) are enriched in high-risk MDS and have a weaker impact on sAML progression and survival.

Conclusions:

• Distinct mutation types (Type 1 and Type 2) play differential roles in MDS and sAML.
• Type 1 mutations are associated with aggressive disease progression and poorer prognosis.
• These findings suggest the potential utility of classifying mutations for MDS disease monitoring and therapeutic strategies.